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tuitary (Fig. 4), and possibly the hypothalamus
(e.g., CRF) and pancreas (e.g., somatostatin), con-
trasts directly the historical disease association
of amyloids both in the brain (e.g., tau, a-
synuclein, Ab, and prion protein) and in the pan-
creas (e.g., insulin and amylin). On the one hand,
this challenges once more the “amyloid hypothe-
sis” that amyloids are the most toxic culprit in
amyloid diseases (31). On the other hand, hor-
mone amyloids may not be (very) toxic because
the hormone amyloids are stored inside the
granules and the amyloid aggregation of hormones
for secretory granule formation may be highly
regulated. This regulation may include the pro-
cessing of prohormones that aggregate more slow-
ly than the hormone counterpart (28) or the
required presence of helper molecules to induce
aggregation, as demonstrated for prolactin (note
that prolactin lacks a prohormone). Furthermore,
the hormone amyloids are stored in an “inert”
membrane container and the amyloid fibrils dis-
sociate upon secretion. Such regulation requires
a functional protein homeostasis. If the protein
homeostasis is altered under certain conditions
such as diet, stress, or age, hormone aggregation
may be out of control and disease-associated amy-
loid aggregation of hormones may occur (see be-
low). Whether such aggregations cause disease, or
are an indirect effect of the protein homeostasis
altered by disease, remains to be determined.
There are many associations between amyloid
processing and function of secretory granules: (i)
Aggregation of hormones into secretory granules
is an intracellular process, and upon secretion not
all of the aggregates dissolve completely (32).
Similarly, Ab may be present in granules (33), and
Ab aggregation may be initiated intracellularly
and end up as a pathological hallmark in the ex-
tracellular space (31). (ii) The malaria drug chloro-
quine interferes with the formation of secretory
granules as well as prion infectivity (34, 35). (iii)
The natural compound curcumin interferes with
both the progression of Alzheimer’s disease (36)
and the release of endocrine hormones (37). (iv)
Several endocrine hormones that may be stored
in secretory granules in an amyloid-like state are
present as amyloids in amyloid diseases. These
include amylin associated with diabetes type II,
calcitonin associated with medullary carcinoma
of the thyroid, and atrial natriuretic factor with
atrial amyloidosis (38). Hence, the presence of
many functional amyloids in the body, together
with the apparent tight link between functional and
disease-associated amyloids in their processing,
biophysical, and biochemical properties, requires a
rethinking of the relationship between aggregation
and function of polypeptides, and the correlation
between amyloid aggregation and toxicity.
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RIP3, an Energy Metabolism Regulator
That Switches TNF-Induced Cell
Death from Apoptosis to Necrosis
Duan-Wu Zhang,1 Jing Shao,1 Juan Lin,1 Na Zhang,1 Bao-Ju Lu,2 Sheng-Cai Lin,1
Meng-Qiu Dong,2 Jiahuai Han1*
Necrosis can be induced by stimulating death receptors with tumor necrosis factor (TNF) or other agonists;
however, the underlying mechanism differentiating necrosis from apoptosis is largely unknown. We
identified the protein kinase receptor-interacting protein 3 (RIP3) as a molecular switch between
TNF-induced apoptosis and necrosis in NIH 3T3 cells and found that RIP3 was required for necrosis in
other cells. RIP3 did not affect RIP1-mediated apoptosis but was required for RIP1-mediated necrosis and
the enhancement of necrosis by the caspase inhibitor zVAD. By activating key enzymes of metabolic
pathways, RIP3 regulates TNF-induced reactive oxygen species production, which partially accounts for
RIP3’s ability to promote necrosis. Our data suggest that modulation of energy metabolism in response to
death stimuli has an important role in the choice between apoptosis and necrosis.
Cell death occurs through morphologicallydistinct processes of apoptosis and ne-crosis (1). Some necrosis is regulated, via
pathways differing from those controlling clas-
sical apoptosis, although necrosis/apoptosis in-
terconnectivity has been observed (1–4). Caspase
inhibition, which distinguishes apoptotic and non-
apoptotic cell death, sometimes shifts apoptosis
to necrosis or enhances necrosis (5–8). Receptors
containing death domains can induce a form of
regulated necrosis through kinase activity of RIP1
(receptor-interacting protein 1) (3, 5, 6). Mito-
chondrial generation of reactive oxygen species
(ROS) is essential for this type of necrosis (9). A
genome-wide small interfering RNA (siRNA)
screen has identified a number of genes involved
in the signaling network of death domain receptor–
mediated necrosis (10), but the precise mechanisms
underlying programmed necrosis and the apoptosis/
necrosis molecular switch remain unclear.
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Although NIH 3T3 cells typically undergo
apoptosis in response to tumor necrosis factor
(TNF) stimulation (10), caspase-independent cell
death has been reported in one NIH 3T3 line
(termed N cells here) (11). We compared the
caspase-dependence of TNF-induced cell death
between NIH 3T3 cells obtained from American
Type Culture Collection (termed A cells here)
and N cells. Benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone (zVAD) inhibited TNF-induced
cell death in A cells (Fig. 1A) but enhanced it in
N cells (Fig. 1B). TNF- or TNF+zVAD–treated N
cells had necrotic morphologies. Because both
cell lines were derived from the same cell popula-
tion, gene expression changes in the N cells could
explain the switch from apoptosis to necrosis in
the NIH 3T3 cells. Affymetrix microarray analysis
revealed that a few genes that have the potential to
regulate cell death or TNF signaling were ex-
pressed differently in A and N cells (table S1). The
expression of RIP3, Calpain 5, Serpinb1a, and
Serpinb9b increased in N cells, whereas expres-
sion of Calpain 6, Aifm1, and Serpine2 decreased.
TNF or zVAD treatment had no effect on the ex-
pression of these genes in either A or N cells. We
decreased expression of the increased genes and
increased expression of the decreased genes in
N cells, then analyzed TNF-induced cell death and
zVAD enhancement of TNF-induced cell death.
Only the siRNA-knockdown of RIP3 in N cells
inhibited zVAD’s enhancement of cell death (fig.
S1). We therefore focused on RIP3.
RIP3 is a protein kinase that has an N-terminal
kinase domain similar to that found in RIP1,
RIP2, and RIP4, but its C-terminal domain has
no sequence similarity to any known protein do-
mains (12, 13). Transient expression of RIP3 in
some cell lines causes cell death (12). Cleavage of
RIP3, RIP1, and RIP4 by caspases was observed
after activation of death receptors (8, 13, 14).
Modulating nuclear factor kB (NF-kB) activation
by means of RIP3 overexpression was observed
(15, 16); however, deletion of RIP3 caused no signs
of deregulated NF-kB signaling (16). The biolog-
ical function of RIP3 is thus largely unknown.
Differing expression of RIP3 in A and N cells
was confirmed by means of Western blotting
(Fig. 1C) (17). To study the role of RIP3, we used
lentiviral vectors to deliver short hairpin RNA
(shRNA) or cDNA into A, N, or other cells be-
cause lentivirus can infect with 100% efficiency.
RIP3 knockdown by means of siRNA in N cells
appeared to switch the type of cell death to that of
A cells because TNF-induced cell death in RIP3-
knockdown N cells was not enhanced but rather
inhibited by zVAD (Fig. 1D). A lacZ-targeting
siRNA (Ctrl) showed no effect on the type of cell
death in N cells (Fig. 1D). RIP3 expression in A
cells switched TNF-induced apoptosis to caspase-
independent cell death (Fig. 1E). zVAD did not
inhibit but rather enhanced cell death (Fig. 1E).
RIP3 kinase activity was required to change the
type of cell death because a catalytically inactive
RIP3 mutant (RIP3-K51A) did not cause A cell
death to become caspase-independent (fig. S2).
Deletion and point mutations revealed that the
RIP1-interacting RHIM (RIP homotypic inter-
action motif) domain in RIP3 is required for
necrosis (fig. S2).
Although zVAD may also participate in the
induction of cell death in some cell lines (10, 18),
we established that RIP3 has a role in necrosis in
the absence of zVAD because it is required for
TNF-induced necrosis in L929 cells (fig. S3A).
We then analyzed whether RIP3 is required for
zVAD-mediated necrosis. zVAD can trigger ne-
crosis of lipopolysaccharides (LPS)– or TNF-
stimulated primary peritoneal macrophages (19)
but failed to promote cell death of RIP3−/−
macrophages stimulated with TNF or LPS (Fig.
1F). It appears that RIP3 functions in necrosis
induced by physiological stimuli and is required
for zVAD to induce or enhance necrosis. Thus,
RIP3 is essential for some forms of necrosis.
RIP1 is required for death receptor agonists to
activate necrosis (5, 6, 8, 18). Although we de-
tected no difference in RIP1 expression in A and
N cells, depletion of RIP1 with shRNA in N
cells inhibited TNF+zVAD–induced necrosis (Fig.
2A). Similarly, depletion of RIP1 from L929 cells
also blocked TNF-induced necrosis (fig. S3B).
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Fig. 1. Effects of RIP3 on type of cell death. (A) Viabilities of A cells treated with medium (Ctrl), zVAD (20
mM), TNF (30 ng/ml), or TNF+zVAD. (B) Viabilities of N cells treated as described in (A). (C) Immunoblotting
analysis with antibody to RIP3. (D) Viabilities of N cells treated with or without (–) a lentiviral vector
encoding LacZ shRNA (Ctrl) or RIP3-shRNAs for 48 hours then stimulated with or without TNF or TNF+zVAD
for 24 hours. RIP3 protein amounts in these cells were analyzed by means of immunoblotting 48 hours after
infection. (E) Viabilities of A cells infected with a lentivirus encoding nothing (vector) or RIP3 for 36 hours
then stimulated with or without TNF or TNF+zVAD for 24 hours. RIP3 protein amounts were analyzed 36
hours after infection. (F) Viabilities of wild-type and RIP3−/− mouse peritoneal macrophages treated with
medium (Ctrl), zVAD, TNF, TNF+zVAD, LPS (100 ng/ml), or LPS+zVAD for 24 hours. Data are the mean T SD
of triplicates [(A), (B), and (D) to (F)] and are representative of two to five experiments [(A) to (F)].
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Therefore, both RIP1 and RIP3 are required for
TNF-induced and zVAD-enhanced necrosis.
Transient RIP1 expression caused cell death
in both wild-type and RIP3−/− mouse embryo
fibroblast (MEF) cells (Fig. 2B). zVAD inhibited
RIP1-induced cell death in RIP3−/− cells but not in
wild-type cells, so RIP3 may have a role in deter-
mining the type of RIP1-induced cell death. Con-
sistently, RIP3-induced cell death was not inhibited
by zVAD. Analyzing RIP1 and RIP3 expression in
the knockout cell lines revealed that the previously
described RIP1−/−MEF line (6) is defective in both
RIP1 and RIP3 expression, and we therefore named
it RIP1−/−RIP3d (Fig. 2B, top). We reconstituted
RIP3 expression in this cell line and named it
RIP1−/−*. RIP1- and RIP3-overexpression–induced
death in RIP1−/−* cells was similar to that ob-
served in wild-type MEF cells, and cell death in
RIP1−/−RIP3d cells was similar to that in RIP3−/−
cells (Fig. 2B), supporting the idea that RIP1
induces apoptosis in the absence of RIP3 and
induces necrosis when RIP3 is present.
RIP1 overexpression induced apoptosis in A
cells and necrosis in RIP3-rich N cells, whereas
RIP3 overexpression induced necrosis in both A
and N cells (Fig. 2C). Unlike MEF cells, necrosis
in these cells was enhanced by zVAD, but only
when RIP3 was present (Fig. 2C). We then found
that zVAD did not enhance RIP1-induced N cell
death when RIP3 was depleted (Fig. 2D). Thus,
RIP3 is required for zVAD to enhance necrosis.
To find RIP3 targets, we identified interacting
proteins during necrosis. Using a lentiviral vector,
we expressed flag-tagged RIP3 in A cells and con-
firmed that flag-RIP3 changed the death type of A
cells to that of N cells. Flag-RIP3 was then purified
in a complex with its associated proteins from A
cells treated with nothing or TNF+zVAD for 30 or
120 min. Protein constituents were identified by
means of liquid chromatography–tandem mass
spectrometry (LC-MS/MS). The raw data set con-
taining nonredundant proteins (table S2) indicated
dynamic changes in the RIP3 complex because
proteins identified in TNF+zVAD–treated sam-
ples were different from the untreated sample.
Seven metabolic enzymes—glycogen phosphoryl-
ase (PYGL), glutamate-ammonia ligase (GLUL),
glutamate dehydrogenase 1 (GLUD1), fructose-
1,6-bisphosphatase 2 (FBP2), fumarate hydratase
(FH), glycosyltransferase 25 domain containing
1 (GLT25D1), and isocitrate dehydrogenase 1
(IDH1)—were identified in the RIP3 complex in
TNF+zVAD–treated cells. PYGL,GLUL, andGLUD1
were confirmed to interact with RIP3 by means
of coimmunoprecipitation of coexpressed proteins
in 293T cells (fig. S4).
PYGL catalyzes the rate-limiting step in the
degradation of glycogen by releasing glucose-1-
phosphate, thereby having a key role in using
reserved glycogen as an energy source. We sought
to determine whether RIP3 and PYGL interact
during necrosis, but were unable to obtain an
antibody to detect endogenous PYGL in N cells.
We therefore established an N cell line stably ex-
pressing hemagglutinin (HA)–PYGL. Immuno-
precipitation using antibodies to RIP3 revealed that
TNF+zVAD treatment for 120 min induced inter-
action of RIP3 and HA-PYGL (Fig. 3A). RIP3
and PYGL interaction was induced by TNF but
not zVAD (Fig. 3B). We incubated flag-PYGL (pu-
rified from 293T cells) with or without glutathione
S-transferase (GST)–RIP3 orGST-RIP3-K51A (pu-
rified from Escherichia coli) in a kinase buffer and
found that RIP3, but not RIP3-K51A, enhanced
PYGL activity in vitro (Fig. 3C). BecauseRIP3may
directly target one or more proteins copurified with
flag-PYGL, we currently can only conclude that
RIP3 directly or indirectly activates PYGL in vitro.
By measuring PYGL activity in N cells and RIP3-
or RIP1-knockdown cells before and after TNF or
TNF+zVAD treatment, we found that RIP3 and
RIP1 are required for TNF- and TNF+zVAD–
increased PYGL activity (Fig. 3D and fig. S5).
The role of RIP3 in regulating PYGL was con-
firmed by use of RIP3−/− peritoneal macrophages
(Fig. 3E). Additionally, expression of RIP3 with
PYGL in 293Tcells enhanced PYGL activity (fig.
S6). To determine whether PYGL is involved in
necrosis, we used siRNAs to deplete PYGL in N
cells and found that reduction of PYGL partially
inhibited TNF+zVAD–induced cell death (Fig. 3F).
Thus, PYGL activation by RIP3 appears to con-
tribute to necrosis.
GLUL is a cytosolic enzyme that catalyzes
the condensation of glutamate (Glu) and ammo-
Fig. 2. Role of RIP3 and RIP1 in apoptosis and necrosis. (A) Viabilities of N cells treated with or without
(–) a lentiviral vector encoding control or RIP1-shRNAs for 48 hours then stimulated with or without TNF or
TNF+zVAD for 24 hours. RIP1 protein amounts were analyzed by means of immunoblotting 48 hours after
infection. (B) Wild-type, RIP3−/−, RIP1−/−*, and RIP1−/−RIP3d MEF cells infected with a lentiviral vector en-
coding RIP1 or RIP3, treated with or without zVAD. Viabilities and RIP1 and RIP3 expression were analyzed
36 hours after infection. (C) N and A cells were treated and analyzed as described in (B). (D) RIP1 and RIP3
expression levels and viabilities of N cells infected with lentiviral vectors expressing control shRNA and RIP3;
RIP1-shRNA and RIP3; control shRNA and RIP1; or RIP3-shRNA and RIP1 and treated with or without zVAD.
Data are the mean T SD of triplicates and are representative of two to three experiments [(A) to (D)].
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nia to form glutamine (Gln). Gln can transfer
into the mitochondria to function as an energy
substrate. GLUD1 is a mitochondrial matrix en-
zyme that converts Glu to a-ketoglutarate. GLUL
and GLUD1 are essential for the use of amino
acid Glu or Gln as substrates for adenosine tri-
phosphate production by means of oxidative
phosphorylation. Enzymatic pathways specifi-
cally used in the mitochondrial oxidation of Gln
have been suggested to sensitize the mitochon-
dria to TNF-induced perturbation (20). We de-
tected increased interaction of endogenous RIP3
with GLUL and GLUD1 after N cells were treated
with TNF or TNF+zVAD (figs. S7, A and B,
and S8, A and B). Recombinant RIP3, but not
RIP3-K51A, can directly increase GLUL activity
(fig. S7C). We were unable to prepare a functional
recombinant protein of GLUD1, but coexpres-
sion of RIP3 with GLUD1 in 293T cells enhanced
activity of GLUD1 (fig. S8C). We were unable
to detect the activities of endogenous GLUL and
GLUD1 in N cells, and therefore were unable to
address their activation in cells. Deletion of either
GLUL or GLUD1 by means of siRNA reduced
TNF+zVAD–induced cell death in N cells (figs. S7D
and S8D), suggesting that GLUL- and GLUD1-
mediated use of Glu or Gln as energy substrates
contributes to necrotic cell death.
Because ROS production is required for
TNF- or TNF+zVAD–induced necrosis in L929
cells, MEFs, and macrophages (6, 9, 19), we
hypothesized that RIP3 might increase energy
metabolism–associated ROS production. We con-
firmed that ROS is required for necrosis of N cells
but not apoptosis of A cells (fig. S9). We found
that depletion of RIP3 in N cells reduced ROS
concentration in TNF+zVAD–treated cells (Fig.
4A) and that increasing RIP3 levels in A cells in-
creased TNF+zVAD–induced ROS production
(Fig. 4B). RIP3 dependence of ROS production
was also confirmed by use of RIP3−/− mac-
rophages (fig. S10). In all cases, the amount of
ROS correlated with caspase-independent cell
death (Fig. 1, D to F). Depletion of PYGL,
GLUL, and GLUD1 by means of siRNA reduced
TNF+zVAD–induced accumulation of ROS
(Fig. 4C and fig. S11), which correlated with cell
death (Fig. 3F and figs. S7D and S8D). Exper-
iments performed by use of energy metabolism
inhibitors suggested that mitochondrial ROS
generated at the ubisemiquinone site has a key
role in TNF cytotoxicity inN cells (fig. S12), which
is consistent with a previous report on L929 cells
(21). Because increasing glucose by breaking down
glycogen and promoting the use of Glu and Gln as
energy substrates all function upstream of ubi-
semiquinone so as to increase energy metabolism,
the role of RIP3 in apoptosis/necrosis switching
should at least partly occur through increasing
energy metabolism–associated ROS production.
A metabolic increase may be needed when
cells are treated with a pleiotropic cytokine such
as TNF. In cells that have sufficient RIP3 expres-
sion, the gateways to using glycogen and Gln or
Glu are readily opened after TNF stimulation.
zVAD may enhance RIP3 function because RIP3
and RIP1 are reported to be cleaved by caspases
(fig. S13) (8, 14). The enhanced metabolism
should be accompanied by increased ROS produc-
tion, which is probably responsible in part for the
function of RIP3 in mediating necrosis (Fig. 4D).
The role of RIP3 in determining the type of cell
death supports the idea that energy metabolism
affects cell-death mechanisms (22, 23).
Necrosis occurs under various physiological
and pathological conditions, and some might
occur in vivo when caspases are inactivated by
S-nitrosylation or other means. Because inhibi-
tion of necrosis by a RIP1 inhibitor has a bene-
ficial effect on ischemic brain injury and other
animal disease models (3, 24), inhibition of RIP3
could be beneficial for diseases that are associ-
ated with necrosis, such as diabetes and cerebral
ischemia. Indeed, deletion of RIP3 improved the
condition of acute pancreatitis in a mouse model
(table S3). RIP3 is a potential drug target for
necrosis-related diseases.
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Reversal of RNA Dominance
by Displacement of Protein
Sequestered on Triplet Repeat RNA
Thurman M. Wheeler,1 Krzysztof Sobczak,1 John D. Lueck,2 Robert J. Osborne,1
Xiaoyan Lin,1 Robert T. Dirksen,2 Charles A. Thornton1*
Genomic expansions of simple tandem repeats can give rise to toxic RNAs that contain expanded repeats.
In myotonic dystrophy, the expression of expanded CUG repeats (CUGexp) causes abnormal regulation
of alternative splicing and neuromuscular dysfunction. We used a transgenic mouse model to show
that derangements of myotonic dystrophy are reversed by a morpholino antisense oligonucleotide,
CAG25, that binds to CUGexp RNA and blocks its interaction with muscleblind-like 1 (MBNL1), a
CUGexp-binding protein. CAG25 disperses nuclear foci of CUGexp RNA and reduces the overall burden
of this toxic RNA. As MBNL1 is released from sequestration, the defect of alternative splicing regulation
is corrected, thereby restoring ion channel function. These findings suggest an alternative use of
antisense methods, to inhibit deleterious interactions of proteins with pathogenic RNAs.
Myotonic dystrophy type 1 (DM1) is rep-resentative of a group of dominantlyinherited disorders in which expression of a toxic RNA leads to neuromuscular degen-eration (1–5). A feature common to these path-ogenic RNAs is the presence of an expanded
repeat. In DM1, the disease-inducing transcript
is the DM protein kinase (DMPK) mRNA con-
taining an expanded CUG repeat in its 3′ untrans-
lated region (3′UTR) (6). These CUG repeats
bind to muscleblind-like 1 (MBNL1), a splicing
regulator, with high affinity (7, 8). Because each
mutant transcript typically contains thousands of
CUG repeats, the capacity for protein binding is
large, causing MBNL1 to become sequestered in
ribonucleoprotein complexes. These complexes
are observed in DM1 cells as foci of CUGexp-
MBNL1 aggregates in the nucleus (7, 9–11).
If sequestration of MBNL1 contributes to
symptoms of DM1, inhibitors of MBNL1-CUGexp
binding may reverse these effects. To test this pos-
sibility, we used CAG25, an antisense 25-nucleotide
morpholino oligonucleotide composed of CAG
repeats. Antisense morpholinos do not trigger
cleavage of their target RNAs (12), which sug-
gests that they could be used to bind CUGexp
RNA and release sequestered proteins, without
risk of degrading other transcripts that contain
CUG repeats. A potential obstacle for this ap-
proach, however, is that CUGexp RNAs form
Fig. 4. Activation of PYGL, GLUL, and GLUD1 by RIP3
contributes to TNF+zVAD–induced ROS production.
(A) ROS levels in N cells treated with a lentiviral vector
expressing control shRNA or RIP3-shRNAs for 48
hours then stimulated with TNF+zVAD for 12 hours.
(B) ROS levels in A cells infected with or without a
lentivirus encoding nothing or RIP3 for 36 hours then
stimulated with TNF+zVAD for 6 hours. (C) ROS levels
in N cells infected with a lentivirus expressing control
shRNA, PYGL-shRNA, GLUL-shRNA, or GLUD1-shRNA
for 48 hours then stimulated with TNF+zVAD for 12
hours. (D) Proposed mechanism for RIP3 in necrosis.
When RIP3 is absent, RIP1-mediated cell death is
apoptotic. High levels of RIP3 switch apoptosis to
necrosis in some cell systems. RIP3 activates PYGL,
increasing the availability of energy substrate glucose;
RIP3 also activates GLUL and GLUD1, increasing Glu
and Gln consumption as energy substrates. These lead
to an increase in energy metabolism and subsequent
overproduction of the oxidative metabolism product,
ROS. ROS is at least in part responsible for RIP3-
mediated necrosis.
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